Overview

A Study Of The Safety And Efficacy Of Levetiracetam (Keppra®) (Ucb L059) In Children With Epilepsy

Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
The open-label study to allow pediatric patients who have participated in prior Levetiracetam (Keppra®) studies to continue their treatment with adequate monitoring and standardized follow-up care until Levetiracetam (Keppra®) is approved for use in children or until the completion of the development program for pediatrics.
Phase:
Phase 3
Details
Lead Sponsor:
UCB Pharma
Treatments:
Etiracetam
Levetiracetam
Piracetam